Literature DB >> 32644257

Control of blood pressure levels in patients with premature coronary artery disease: Results from the Genetics of Atherosclerotic Disease study.

Esteban Jorge-Galarza1, Froylan D Martínez-Sánchez1, Cesar I Javier-Montiel1, Aida X Medina-Urrutia1, Carlos Posadas-Romero1, María C González-Salazar1, Horacio Osorio-Alonso2, Abraham S Arellano-Buendía2, Juan G Juárez-Rojas1.   

Abstract

High blood pressure (BP) is the major cardiovascular-risk factor for coronary artery disease (CAD), principally in young patients who have an important and increasing socioeconomic burden. Despite the Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7), recommended BP target <140/90 mm Hg for patients with stable CAD, in 2017 the American College of Cardiology and the American Heart Association (ACC/AHA) updated BP target to <130/80 mm Hg. We aimed to analyze the prevalence of BP control in patients with premature CAD using both criteria. In addition, antihypertensive therapy, lifestyle, clinical, and sociodemographic characteristics of the patients were evaluated in order to identify factors associated with the achievement of BP targets. The present study included 1206 patients with CAD diagnosed before 55 and 65 years old in men and women, respectively. Sociodemographic, clinical, and biochemical data were collected. The results indicate that 85.6% and 77.5% of subjects with premature CAD achieved JNC-7 non-strict and ACC/AHA strict BP target, respectively. Consistently, number of antihypertensive drugs and hypertension duration >10 years were inversely associated with BP targets, whereas total physical activity and smoking were directly associated with BP targets, regardless of BP criteria. Considering that age, gender, and hypertension duration are non-modifiable cardiovascular-risk factors, our results highlight the need for more effective strategies focused on increase physical activity and smoking cessation in young patients with CAD. These healthier lifestyles changes should favor the BP target achievement and reduce the socioeconomic and clinical burden of premature CAD.
© 2020 Wiley Periodicals LLC.

Entities:  

Keywords:  antihypertensive drugs; blood pressure; cardiovascular-risk factors; hypertension; premature coronary artery disease

Mesh:

Substances:

Year:  2020        PMID: 32644257      PMCID: PMC8029811          DOI: 10.1111/jch.13942

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  35 in total

Review 1.  Risk factors of premature coronary artery disease in Iran: A systematic review and meta-analysis.

Authors:  Hoorak Poorzand; Konstantinos Tsarouhas; Seyyed Amin Hozhabrossadati; Nastaran Khorrampazhouh; Yones Bondarsahebi; Flora Bacopoulou; Ramin Rezaee; Reza Jafarzadeh Esfehani; Negar Morovatdar
Journal:  Eur J Clin Invest       Date:  2019-05-18       Impact factor: 4.686

2.  Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study.

Authors:  Emmanuelle Vidal-Petiot; Ian Ford; Nicola Greenlaw; Roberto Ferrari; Kim M Fox; Jean-Claude Tardif; Michal Tendera; Luigi Tavazzi; Deepak L Bhatt; Philippe Gabriel Steg
Journal:  Lancet       Date:  2016-08-30       Impact factor: 79.321

3.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

4.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

5.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245

Review 6.  The Real Role of β-Blockers in Daily Cardiovascular Therapy.

Authors:  Csaba András Dézsi; Veronika Szentes
Journal:  Am J Cardiovasc Drugs       Date:  2017-10       Impact factor: 3.571

7.  Control of blood pressure levels in patients with premature coronary artery disease: Results from the Genetics of Atherosclerotic Disease study.

Authors:  Esteban Jorge-Galarza; Froylan D Martínez-Sánchez; Cesar I Javier-Montiel; Aida X Medina-Urrutia; Carlos Posadas-Romero; María C González-Salazar; Horacio Osorio-Alonso; Abraham S Arellano-Buendía; Juan G Juárez-Rojas
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-09       Impact factor: 3.738

8.  The ABCA1 gene R230C variant is associated with decreased risk of premature coronary artery disease: the genetics of atherosclerotic disease (GEA) study.

Authors:  Teresa Villarreal-Molina; Carlos Posadas-Romero; Sandra Romero-Hidalgo; Erika Antúnez-Argüelles; Araceli Bautista-Grande; Gilberto Vargas-Alarcón; Eric Kimura-Hayama; Samuel Canizales-Quinteros; Juan Gabriel Juárez-Rojas; Rosalinda Posadas-Sánchez; Guillermo Cardoso-Saldaña; Aída Medina-Urrutia; María Del Carmen González-Salazar; Rocío Martínez-Alvarado; Esteban Jorge-Galarza; Alessandra Carnevale
Journal:  PLoS One       Date:  2012-11-09       Impact factor: 3.240

9.  Validity of the modified Baecke questionnaire: comparison with energy expenditure according to the doubly labeled water method.

Authors:  Emmy M Hertogh; Evelyn M Monninkhof; Evert G Schouten; Petra Hm Peeters; Albertine J Schuit
Journal:  Int J Behav Nutr Phys Act       Date:  2008-05-27       Impact factor: 6.457

10.  Prevalence and risk factors of premature coronary artery disease in patients undergoing coronary angiography in Kurdistan, Iraq.

Authors:  Ameen Mosa Mohammad; Hekmat Izzat Jehangeer; Sabri Khalif Shaikhow
Journal:  BMC Cardiovasc Disord       Date:  2015-11-18       Impact factor: 2.298

View more
  4 in total

Review 1.  Mecanismos moleculares de los efectos benéficos de la alicina sobre la enfermedad cardiovascular.

Authors:  Abraham S Arellano-Buendía; Juan G Juárez-Rojas; Fernando E García-Arroyo; Laura G Sánchez-Lozada; Horacio Osorio-Alonso
Journal:  Arch Cardiol Mex       Date:  2022

2.  Gender differences in factors associated with the health literacy of hospitalized older patients with chronic diseases: A cross-sectional study.

Authors:  Shuting Sun; Jinjin Lu; Yawen Wang; Ya Wang; Lihao Wu; Saiqiong Zhu; Xiuyun Zheng; Xueqin Lu; Hongbo Xu
Journal:  Front Public Health       Date:  2022-08-10

Review 3.  Cellular Mechanisms Underlying the Cardioprotective Role of Allicin on Cardiovascular Diseases.

Authors:  José L Sánchez-Gloria; Abraham S Arellano-Buendía; Juan G Juárez-Rojas; Fernando E García-Arroyo; Raúl Argüello-García; Fausto Sánchez-Muñoz; Laura G Sánchez-Lozada; Horacio Osorio-Alonso
Journal:  Int J Mol Sci       Date:  2022-08-13       Impact factor: 6.208

4.  Control of blood pressure levels in patients with premature coronary artery disease: Results from the Genetics of Atherosclerotic Disease study.

Authors:  Esteban Jorge-Galarza; Froylan D Martínez-Sánchez; Cesar I Javier-Montiel; Aida X Medina-Urrutia; Carlos Posadas-Romero; María C González-Salazar; Horacio Osorio-Alonso; Abraham S Arellano-Buendía; Juan G Juárez-Rojas
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-09       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.